<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-17T12:58:30Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:11351/12714" metadataPrefix="didl">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:11351/12714</identifier><datestamp>2025-10-24T10:27:18Z</datestamp><setSpec>com_2072_378070</setSpec><setSpec>com_2072_378040</setSpec><setSpec>col_2072_378092</setSpec></header><metadata><d:DIDL xmlns:d="urn:mpeg:mpeg21:2002:02-DIDL-NS" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="urn:mpeg:mpeg21:2002:02-DIDL-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/did/didl.xsd">
   <d:DIDLInfo>
      <dcterms:created xmlns:dcterms="http://purl.org/dc/terms/" xsi:schemaLocation="http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/dcterms.xsd">2025-10-24T10:27:18Z</dcterms:created>
   </d:DIDLInfo>
   <d:Item id="hdl_11351_12714">
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <dii:Identifier xmlns:dii="urn:mpeg:mpeg21:2002:01-DII-NS" xsi:schemaLocation="urn:mpeg:mpeg21:2002:01-DII-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dii/dii.xsd">urn:hdl:11351/12714</dii:Identifier>
         </d:Statement>
      </d:Descriptor>
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
               <dc:title>Systematic Review and Meta-Analysis of Extracorporeal Photopheresis for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease</dc:title>
               <dc:creator>DeFilipp, Zachariah</dc:creator>
               <dc:creator>Holderried, Tobias</dc:creator>
               <dc:creator>Mehra, Varun</dc:creator>
               <dc:creator>Michonneau, David</dc:creator>
               <dc:creator>Pashley, Alex</dc:creator>
               <dc:creator>Fox, Maria Laura</dc:creator>
               <dc:subject>Avaluació de resultats (Assistència sanitària)</dc:subject>
               <dc:subject>Malalties cròniques</dc:subject>
               <dc:subject>Esteroides - Ús terapèutic</dc:subject>
               <dc:subject>Empelt contra l'hoste, Malaltia de l' - Fototeràpia</dc:subject>
               <dc:subject>ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome</dc:subject>
               <dc:subject>DISEASES::Immune System Diseases::Graft vs Host Disease</dc:subject>
               <dc:subject>Other subheadings::Other subheadings::/therapy</dc:subject>
               <dc:subject>CHEMICALS AND DRUGS::Polycyclic Compounds::Fused-Ring Compounds::Steroids</dc:subject>
               <dc:subject>Other subheadings::Other subheadings::/therapeutic use</dc:subject>
               <dc:subject>DISEASES::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Chronic Disease</dc:subject>
               <dc:subject>ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Phototherapy::Ultraviolet Therapy::PUVA Therapy::Photopheresis</dc:subject>
               <dc:subject>TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento</dc:subject>
               <dc:subject>ENFERMEDADES::enfermedades del sistema inmune::enfermedad injerto contra huésped</dc:subject>
               <dc:subject>Otros calificadores::Otros calificadores::/terapia</dc:subject>
               <dc:subject>COMPUESTOS QUÍMICOS Y DROGAS::compuestos policíclicos::compuestos con anillos de fusión::esteroides</dc:subject>
               <dc:subject>Otros calificadores::Otros calificadores::/uso terapéutico</dc:subject>
               <dc:subject>ENFERMEDADES::afecciones patológicas, signos y síntomas::procesos patológicos::atributos de la enfermedad::enfermedad crónica</dc:subject>
               <dc:subject>TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::fototerapia::tratamiento con rayos ultravioleta::tratamiento PUVA::fotoféresis</dc:subject>
               <dc:description>Chronic graft-versus-host disease; Extracorporeal photopheresis; Steroid-refractory disease</dc:description>
               <dc:description>Enfermedad crónica de injerto contra huésped; Fotoféresis extracorpórea; Enfermedad refractaria a esteroides</dc:description>
               <dc:description>Malaltia crònica d'empelt contra hoste; Fotofèresi extracorpòria; Malaltia refractaria als esteroides</dc:description>
               <dc:description>The objective of this meta-analysis (MA) was to evaluate the efficacy and safety of extracorporeal photopheresis (ECP) for the treatment of steroid-refractory chronic graft-versus-host disease (SR-cGvHD). A systematic literature review (SLR) was conducted according to PRISMA guidelines, followed by a feasibility assessment (FA) to assess potential between-study heterogeneity in the meta-analysis (MA). Random-effects MAs were performed for overall survival (OS), failure-free survival (FFS), overall response rate (ORR) and skin-specific response. A subgroup analysis was conducted to explore the effect of NIH assessment criteria. The SLR identified 627 records; 45 unique studies were ultimately included in the MA. For patients treated with ECP, at Month 12, the pooled OS rate was 83.97% and the pooled FFS rate was 60.79%. ORR was 45.34% at Months 3 to 4 and 58.23% at Months 6 to 8. Subgroup analyses showed no significant difference in ORR between studies utilizing NIH criteria and those utilizing non-NIH criteria. Skin-specific response was 34.86% at Months 2 to 3 and 54.22% at Months 4 to 6. There was considerable heterogeneity across all analyses, with I2 values ranging from 65% to 91%. This SLR and MA indicates that ECP results in favorable outcomes in the treatment of SR-cGvHD, including OS, FFS and ORR.</dc:description>
               <dc:description>This study was funded by Mallinckrodt Pharmaceuticals.</dc:description>
               <dc:date>2025-10-24T10:27:18Z</dc:date>
               <dc:date>2025-10-24T10:27:18Z</dc:date>
               <dc:date>2025-03-07T11:43:26Z</dc:date>
               <dc:date>2025-03-07T11:43:26Z</dc:date>
               <dc:date>2024</dc:date>
               <dc:date>2025-02</dc:date>
               <dc:type>info:eu-repo/semantics/article</dc:type>
               <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
               <dc:identifier>http://hdl.handle.net/11351/12714</dc:identifier>
               <dc:relation>Transplantation and Cellular Therapy;31(2)</dc:relation>
               <dc:relation>https://doi.org/10.1016/j.jtct.2024.11.004</dc:relation>
               <dc:rights>Attribution-NonCommercial-NoDerivatives 4.0 International</dc:rights>
               <dc:rights>http://creativecommons.org/licenses/by-nc-nd/4.0/</dc:rights>
               <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
               <dc:publisher>Elsevier</dc:publisher>
               <dc:source>Scientia</dc:source>
            </oai_dc:dc>
         </d:Statement>
      </d:Descriptor>
   </d:Item>
</d:DIDL></metadata></record></GetRecord></OAI-PMH>